I-Mab Logo
  • Investors
  • Careers
  • Contact
  • 简体中文
  • About
    Who We Are

    A global innovative biotech company

    Value Creation

    Laser-focused on delivering innovative therapies to patients in need

    Leadership Team

    A world-class global leadership team

    People & Culture

    People are the cornerstone of our success

    Commitment to ESG

    Committed to the highest environmental, social and governance standards

  • Innovation
    Science

    Our cutting-edge science focuses on fine-tuning the immune network in cancer

    Publications & Presentations

    A compilation of our latest publications and presentations

    Operations

    An integrated research, development, manufacturing and commercialization strategy

  • Products
    Product Pipeline

    We have an innovative and advanced immuno-oncology clinical pipeline

    Clinical Trials

    We work closely with global investigators to carefully conduct and monitor clinical studies

  • Partnerships
  • News & Events
    News

    Our Latest News

    Events

    Our Latest Events

I-Mab Logo
  • About
    • Who We Are
    • Value Creation
    • Leadership Team
    • People and Culture
    • Commitment to ESG
  • Innovation
    • Science
    • Publications
    • Operations
  • Products
    • Product Pipeline
    • Clinical Trials
  • Partnerships
  • News & Events
    • News
    • Events
  • Investors
  • Careers
  • Contact
  • 简体中文

Media Reports

  • Press Releases
  • Media Reports
  • Partner News

2022.02.03

Endpoints: I-Mab expands manufacturing for multiple myeloma antibody; Granules issued ‘minor observations’ after inspection

Read at Endpoints

2021.07.09

FierceBiotech: I-Mab boards popular mRNA train with 2 biotech collaborations

Read at FierceBiotech

2021.05.19

2021.5-Endpoints: #ASCO21: AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody

Read at Endpoints

2021.05.19

2021.5-FierceBiotech: ASCO: I-Mab’s checkpoint inhibitor drug helper uliledlimab sees early promise in Tecentriq cancer combo test

Read at FierceBiotech

2021.04.27

2021.4-Biocentury: I-Mab is pursuing mRNA therapies, eyeing orally delivered antibodies for ‘third wave’ of its immuno-oncology pipeline

Read at Biocentury

2021.04.15

2021.4-Biocentury: Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

Read at Biocentury

2021.03.11

2021.3-Biocentury: I-Mab signs first two deals of immuno-oncology discovery initiative

Read at Biocentury

2021.01.04

Endpoints: I-Mab —A Biotech on the Rise with Inspired Science

Read at Endpoints

2020.09.13

Nature BioPharma Dealmakers, September 2019: I-Mab Biopharma company profile

Read at Nature BioPharma Dealmakers

2020.09.05

2020.9-Biocentury: Deal with AbbVie, PIPE triples I-Mab’s cash, positions biotech to be among China’s CD47 leaders

Read at Biocentury

Posts navigation

1 2 3 Next

Sitemap

  • Home
  • About
  • Innovation
  • Products
  • Partnerships
  • News & Events
  • Investors
  • Careers
  • Contact
  • 简体中文

Follow Us

  • LinkedIn
  • Twitter

Copyright © 2023 I-MAB Biopharma Co., Ltd. All Rights Reserved.

沪ICP备17007960号-2 | 沪公网安备31011502018701号